DExSI: A new tool for the rapid quantitation of 13C-labelled metabolites detected by GC-MS
Although a physician will oversee your treatment plan, many clients choose to inject themselves at home one to three times per week rather than make frequent trips to their doctors office
In preclinical studies, BPC-157 demonstrated an exceptionally wide therapeutic window with no observed toxicity even at high doses. Sikiric et al., Current Pharmaceutical Design Long-Term Safety As of now, long-term human safety data is lacking
They only reconstitute what they need
The scope of the antimicrobial resistance challenge
As the anti-doping guidance states, "Because BPC-157 has not been extensively studied in humans, no one knows if there is a safe dose, or if there is any way to use this compound safely" [21]